Tetravac injektionsvæske, suspension Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

tetravac injektionsvæske, suspension

sanofi pasteur europe - bordetella pertussis, filamentøs hæmagglutinin (fha), bordetella pertussis, toxoid, clostridium tetani, stamme harvard 49205, toxoid, corynebacterium diphtheria, stamme utrecht cn 2000 msm iii, toxoid, poliovirus type 1, stamme mahoney (inaktiveret), poliovirus type 2, stamme mef-1 (inaktiveret), poliovirus type 3, stamme saukett (inaktiveret) - injektionsvæske, suspension

Vepicombin Novum 85.000 IE/ml granulat til oral opløsning Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

vepicombin novum 85.000 ie/ml granulat til oral opløsning

takeda pharma a/s - phenoxymethylpenicillinkalium - granulat til oral opløsning - 85.000 ie/ml

Zantac 300 mg brusetabletter Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

zantac 300 mg brusetabletter

paranova danmark a/s - ranitidinhydrochlorid - brusetabletter - 300 mg

Zarator 10 mg tyggetabletter Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 10 mg tyggetabletter

upjohn eesv - atorvastatincalcium (trihydrat) - tyggetabletter - 10 mg

Zarator 20 mg tyggetabletter Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 20 mg tyggetabletter

upjohn eesv - atorvastatincalcium (trihydrat) - tyggetabletter - 20 mg

Dengvaxia União Europeia - dinamarquês - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. brug af dengvaxia bør være i overensstemmelse med de officielle anbefalinger.